Comparison of systemic and topical isotretinoin in the treatment of facial lichen planopilaris: A randomized controlled trial. (4th January 2022)

• Record Type: Journal Article
• Authors: Saber, Mina; Bahraminejad, Mahsa; Fatemi Naeini, Farahnaz; Mohaghegh, Fatemeh; Faghihi, Gita; Hosseini, Sayed Mohsen
• Is Part Of: Journal of cosmetic dermatology. Volume 21:Number 9(2022)
• Page Start: 3896
• Page End: 3904
• Publication Date: 2022-01-04
• Subjects: facial papule -- frontal fibrosing alopecia -- isotretinoin -- lichen planopilaris -- management -- scarring alopecia -- treatment -- vellus hair follicle; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.14730
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: Background: Facial papules reflecting the lichenoid inflammation of facial vellus hair follicles can occur in the backgrounds of frontal fibrosing alopecia, lichen planopilaris (LPP), or even alone. In the present study, we aimed to compare systemic and topical isotretinoin in the treatment of facial LPP. Method: In a prospective randomized trial, 26 patients with facial LPP were randomly allocated to receive either 20 mg/day oral isotretinoin or isotretinoin 0.05% gel every night for 6 months. Global Aesthetic Improvement Scale (GAIS) and patient's satisfaction questionnaire were used at 1, 3, and 6 months after treatment to evaluate the outcomes. Results: In both oral and topical isotretinoin groups, facial papules were significantly improved at all follow‐up visits, resulting in statistically significant improvements ( p = 0.005 and p = 0.007, respectively, for oral and topical groups) in GAIS score mean difference from month 1 to month 6. Overall levels of patient satisfaction were high in both groups, and no significant difference was observed between two groups ( p = 0.107). However, the mean GAIS score at 3 and 6 months after treatment showed significantly greater improvements in oral isotretinoin group compared to topical group (1.85 ± 0.62 vs. 1.03 ± 0.49 at month 3, p = 0.004; 2.45 ± 54 vs. 1.59 ± 0.62 at month 6, p = 0.008). Overall, patients could well tolerate the treatments; however, topical therapy was associated with fewer side effects. Discussion: Both oral and topical isotretinoin were found to be effective in improving facial papules; however, oral isotretinoin was significantly more efficacious. Considering safety profile of topical isotretinoin, it can be administrated as maintenance therapy for patients with facial LPP.